Tumor and stromal chemoresistance

Alberto Villanueva Garatachea / David Garcia Mollevi

PRINCIPAL INVESTIGATORS
  • Maria Lourdes Farre Vallve
PREDOCTORAL RESEARCHERS
  • Juan Francisco Martín Tejera
  • Nerea Albert Colome
  • Gemma Garcia Vicien
  • Daniel Alvarez Villanueva
SCIENTIFIC SUPPORT
  • Monica Calaf Sanjuanes
  • Maria Bañuls Ferrando
  • Isabel Puig Povedano
Cancer
Oncobell

Scientific production

15

PAPERS

Impact factor: 176,191

6 PUBLICATIONS IN FIRST DECILE

14 PUBLICATIONS IN FIRST QUARTILE

12 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Morral, Clara; Stanisavljevic, Jelena; Hernando-Momblona, Xavier; Mereu, Elisabetta; Alvarez-Varela, Adrian; Cortina, Carme; Stork, Diana; Slebe, Felipe; Turon, Gemma; Whissell, Gavin; Sevillano, Marta; Merlos-Suarez, Anna; Casanova-Marti, Angela; Moutinho, Catia; Lowe, Scott W.; Dow, Lukas E.; Villanueva, Alberto; Sancho, Elena; Heyn, Holger; Batlle, Eduard. Zonation of Ribosomal DNA Transcription Defines a Stem Cell Hierarchy in Colorectal Cancer. CELL STEM CELL. 10.1016/j.stem.2020.04.012
  • Carrillo-Reixach, Juan; Torrens, Laura; Simon-Coma, Marina; Royo, Laura; Domingo-Sabat, Montserrat; Abril-Fornaguera, Jordi; Akers, Nicholas; Sala, Margarita; Ragull, Sonia; Arnal, Magdalena; Villalmanzo, Nuria; Cairo, Stefano; Villanueva, Alberto; Kappler, Roland; Garrido, Marta; Guerra, Laura; Sabado, Constantino; Guillen, Gabriela; Mallo, Mar; Pineyro, David; Vazquez-Vitali, Maria; Kuchuk, Olga; Elena Mateos, Maria; Ramirez, Gema; Lopez Santamaria, Manuel; Mozo, Yasmina; Soriano, Aroa; Grotzer, Michael; Branchereau, Sophie; Garcia de Andoin, Nagore; Lopez-Ibor, Blanca; Lopez-Almaraz, Ricardo; Antonio Salinas, Jose; Torres, Barbara; Hernandez, Francisco; Javier Uriz, Jose; Fabre, Monique; Blanco, Julia; Paris, Claudia; Bajciova, Viera; Laureys, Genevieve; Masnou, Helena; Clos, Ariadna; Belendez, Cristina; Guettier, Catherine; Sumoy, Lauro; Planas, Ramon; Jorda, Mireia; Nonell, Lara; Czauderna, Piotr; Morland, Bruce; Sia, Daniela; Losic, Bojan; Buendia, Marie Annick; Rosa Sarrias, Maria; Llovet, Josep M.; Armengol, Carolina. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. JOURNAL OF HEPATOLOGY. 10.1016/j.jhep.2020.03.025
  • Esteve-Puig R; Climent F; Piñeyro D; Domingo-Domenech E; Davalos V; Encuentra M; Rea A; Espejo-Herrera N; Soler M; Lopez M; Ortiz-Barahona V; Tapia G; Navarro JT; Cid J; Farre L; Villanueva A; Casanova I; Mangues R; Santamarina-Ojeda P; Fernández AF; Fraga MF; Piris MA; Kol N; Avrahami C; Moshitch-Moskkovitz S; Rechavi G; Sureda A; Esteller M. Epigenetic Loss of m1A RNA Demethylase ALKBH3 in Hodgkin Lymphoma Targets Collagen Conferring Poor Clinical Outcome. BLOOD. 10.1182/blood.2020005823
  • Fernandes Neto, Joao M.; Nadal, Ernest; Bosdriesz, Evert; Ooft, Salo N.; Farre, Lourdes; McLean, Chelsea; Klarenbeek, Sjoerd; Jurgens, Anouk; Hagen, Hannes; Wang, Liqin; Felip, Enriqueta; Martinez-Marti, Alex; Vidal, August; Voest, Emile; Wessels, Lodewyk F. A.; van Tellingen, Olaf; Villanueva, Alberto; Bernards, Rene. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. NATURE COMMUNICATIONS. 10.1038/s41467-020-16952-9
  • Latacz E, van Dam PJ, Vanhove C, Llado L, Descamps B, Ruiz N, Joye I, Grünhagen D, Van Laere S, Dirix P, Mollevi DG, Verhoef C, Dirix L, Vermeulen P . Can medical imaging identify the histopathological growth patterns of liver metastases?. SEMINARS IN CANCER BIOLOGY. 10.1016/j.semcancer.2020.07.002

Research highlights

PROJECTS

8 Competitive projects
8 Non competitive projects
1 Clinical trial

Selected projects

  • AEC21010. Mechanisms of innate and acquire resistance to immune checkpoint inhibitors in orthoxenografts/PDOX and immunorthoxenografts/immunoPDOX from lung (NSCLC) and bladder cancer. (PRYGN211363VILL). Importe Concedido:299.963,75€. IP:VILLANUEVA GARATACHEA,ALBERTO.
  • 20FIS014. Genetic bases of tumor cell resitance to immune checkpoint inhibitors in orthoxenografts/ PDOX derived from three cisplatin-based treated tumors: NSCLC, bladder and ovarian cancer. (PI19/01320). Importe Concedido:147.620,00€. 2020-2022. IP:VILLANUEVA GARATACHEA,ALBERTO.
  • 18CEE005. EDIReX:EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts. (731105). COMISSIÓ EUROPEA. Importe Concedido:121.146,25€. 2018-2022. IP:VILLANUEVA GARATACHEA,ALBERTO.
  • 19FIS027. Reprogramación de fibroblastos asociados a carcinoma intratumorales en metástasis hepáticas de carcinoma colorrectal. (PI18/01140). ISCIII. Importe Concedido:111.320,00€. 2019-2023. IP:GARCIA MOLLEVI,DAVID.
  • 20MAR007. Humanized nanomedicines selectively killing CXCR4+ cancer cells for Acute Myeloid Leukemia therapy. (201941-32). F. I. DE RECERCA DEL HOSPITAL DE LA SANTA CREU I SANT PAU; FUNDACIO IDIBELL; FUNDACIÓ LA MARATÓ DE TV3; UNIV. AUTONOMA BARCELONA. Importe Concedido:99.960,81€. 2020-2023. IP:FARRE VALLVE,MARIA LOURDES.